Search results
Showing 4231 to 4245 of 8927 results
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
This indicator covers the percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 month. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM98.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
See a complete list of all our guidance and quality standards currently open for consultation
Our events help you meet experts and stay connected with peers.
Home News Articles {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"
Home News...
Health inequalities are differences in health across the population, and between different groups in society, that are systematic, unfair and avoidable.
Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for HTG279Show all sections
Sections for HTG279
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Home Get involved People and communities - putting you at the heart of our work {"@context":"http://schema.org","@type":"BreadcrumbList","itemLis
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.